Can SkyePharma PLC (+78%), Cairn Energy PLC (+63%) And Vedanta Resources plc (+56%) Keep On Climbing?

Are SkyePharma PLC (LON: SKP), Cairn Energy PLC (LON: CNE) And Vedanta Resources plc (LON: VED) set for big wins?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceuticals, oil and gas exploration, and mining — quite a heady combination these days, but all three shares have been rising strongly of late and could have much further to go.

Look at SkyePharma (LSE: SKP). Its shares have climbed by 78% from their 52-week low in August 2015, to 457p — and if that’s not enough for you, over the past five years they’ve soared by a massive 990%! But, can it keep going?

I’d say there’s a very good possibility that it can. SkyePharma, once a lossmaking blue-sky possibility, has crossed the line into profitability and earnings per share (EPS) have been swelling nicely. In fact, though there’s a fall in EPS forecast for this year, the subsequent growth pencilled-in for 2017 would put the shares on a P/E of a little over 15 — and I reckon that’s very attractive for a growth candidate.

What’s more, SkyePharma’s speciality is in developing drug delivery technology rather than the drugs themselves — things like oral, topical, inhalable and injectable delivery systems. And to me that makes the firm look like a lower risk “picks and shovels” candidate, whose products are used by big-name drug developers including GlaxoSmithKline, Novartis, Roche and others.

Oil strength

The rising price of oil, which is oscillating around the $40 level, has helped boost Cairn Energy (LSE: CNE) shares by 63% to 208p since their low of 20 January. Full-year results released on 15 March contributed too. Chief executive Simon Thomson said of the firm’s offshore Senegal prospects that the results have confirmed “the scale and extent of the significant resource base in this world class asset“.

A risk with Cairn Energy is that it’s still at the cash-burn stage and there are no profits within the forecast horizon yet. But at 31 December there was a tidy $603m net cash on the books, and the company still has undrawn lending facilities and letters of credit that should add around another $500m to its available cash. Cairn, then, isn’t going to be hit by the kind of debt squeeze in the near future that some of its rivals will face.

With some impressive assets under development and a positive brokers’ stance, Cairn looks promising to me.

Mining resurgence

India-focused Vedanta Resources (LSE: VED) has seen its shares drop 41% over the past 12 months as the commodities slump has continued to bite, but since a low on 18 January there has been a 56% climb to 320.5p. With the firm’s main products being copper, zinc, aluminium, lead, iron ore and petroleum, the recent recoveries in minerals and oil prices have both given the shares a leg up.

Vedanta, like the rest of the sector, isn’t out of the woods yet. With earnings having plummeted over the past few years, the company has three years of losses forecast — and its dividend, set to yield 4.5% for the year to March 2016, is surely not going to be maintained.

But the losses should be relatively small, and the long-term future is surely solid, even if analysts currently have Vedanta as a sell.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »